Lung Cancer
Bayer funds educational programs on non-small cell lung cancer, focusing on biomarkers, TRK-fusion, and precision medicine to advance diagnosis, treatment, and multidisciplinary care.
Funder: Bayer
Due Dates: Rolling (monthly review; submit anytime)
Funding Amounts: Amount not specified; varies by program scope and proposed budget.
Summary: Supports educational programs advancing knowledge in non-small cell lung cancer, especially biomarkers, TRK-fusion, and precision medicine.
Key Information: Allow at least 45 days from submission for response; programs must comply with ACCME guidelines and provide detailed supporting documentation.
Description
Bayer Oncology Medical Affairs is seeking applications for educational grants focused on non-small cell lung cancer (NSCLC), particularly adenocarcinoma. The grant aims to support programs that educate healthcare professionals and patients/caregivers on the latest developments in NSCLC diagnosis, treatment, and management. Emphasis is placed on the role of biomarkers, biomarker-driven testing strategies, TRK-fusion testing, implications of TRK pathway aberrations, and the efficacy and safety of approved TRK inhibitors. The initiative encourages a multidisciplinary approach to precision medicine, particularly in community and regional healthcare settings.
